<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40916045</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1930-739X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Obesity (Silver Spring, Md.)</Title><ISOAbbreviation>Obesity (Silver Spring)</ISOAbbreviation></Journal><ArticleTitle>Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/oby.70014</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5&#x2009;mg and/or MTD of 15&#x2009;mg or 10&#x2009;mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI &#x2265;&#xa0;30&#x2009;kg/m<sup>2</sup> or &#x2265;&#xa0;27&#x2009;kg/m<sup>2</sup> with &#x2265;&#xa0;1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.e., &lt;&#x2009;5% BW change) between Weeks 48 and 60.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants are mostly female (65%) with a mean&#x2009;&#xb1;&#x2009;SD age of 47&#x2009;&#xb1;&#x2009;13&#x2009;years, BW 114&#x2009;&#xb1;&#x2009;27&#x2009;kg, BMI 40&#x2009;&#xb1;&#x2009;8&#x2009;kg/m<sup>2</sup>, and waist circumference 119&#x2009;&#xb1;&#x2009;18&#x2009;cm.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The SURMOUNT-MAINTAIN trial will evaluate whether reducing or continuing the tirzepatide dose as a long-term treatment option may help maintain the reduced BW initially achieved with tirzepatide MTD versus switching to placebo. Combined, this study may provide additional evidence to help tailor patient-centered strategies for maintenance of BW reduction in adults living with obesity.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier: NCT06047548.</AbstractText><CopyrightInformation>&#xa9; 2025 Eli Lilly and Company and The Author(s). Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Deborah B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronne</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0002-9890-9401</Identifier><AffiliationInfo><Affiliation>Comprehensive Weight Control Center, Division of Endocrinology, Diabetes &amp; Metabolism, Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Sean</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0111-1530</Identifier><AffiliationInfo><Affiliation>University of Toronto and Wharton Weight Management Clinic, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bays</LastName><ForeName>Harold E</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0001-9912-1408</Identifier><AffiliationInfo><Affiliation>Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Valderas</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arad</LastName><ForeName>Avigdor D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Palash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Julia P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-9561-0183</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senyucel</LastName><ForeName>Cagri</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Clare J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06047548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Eli Lilly and Company</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obesity (Silver Spring)</MedlineTA><NlmUniqueID>101264860</NlmUniqueID><ISSNLinking>1930-7381</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SURMOUNT&#x2010;MAINTAIN</Keyword><Keyword MajorTopicYN="N">antiobesity medication</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">obesity management medication</Keyword><Keyword MajorTopicYN="N">tirzepatide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>7</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40916045</ArticleId><ArticleId IdType="doi">10.1002/oby.70014</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>American Medical Association House of Delegates, &#x201c;Resolution: 420 (A&#x2010;13). Recognition of Obesity as a Disease,&#x201d; 2013, https://media.npr.org/documents/2013/jun/ama&#x2010;resolution&#x2010;obesity.pdf.</Citation></Reference><Reference><Citation>Council on Science and Public Health, &#x201c;Is Obesity a Disease? (Resolution 115&#x2010;A&#x2010;12). Report Number: 3&#x2010;A&#x2010;13,&#x201d; 2013, https://www.ama&#x2010;assn.org/sites/ama&#x2010;assn.org/files/corp/media&#x2010;browser/public/about&#x2010;ama/councils/Council%20Reports/council&#x2010;on&#x2010;science&#x2010;public&#x2010;health/a13csaph3.pdf.</Citation></Reference><Reference><Citation>M. D. Jensen, D. H. Ryan, K. A. Donato, et&#xa0;al., &#x201c;Executive Summary: Guidelines (2013) for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society Published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a Systematic Review From the Obesity Expert Panel, 2013,&#x201d; Obesity 22, no. S2 (2014): S5&#x2013;S39.</Citation></Reference><Reference><Citation>B. Lauby&#x2010;Secretan, C. Scoccianti, D. Loomis, et&#xa0;al., &#x201c;Body Fatness and Cancer&#x2014;Viewpoint of the IARC Working Group,&#x201d; New England Journal of Medicine 375, no. 8 (2016): 794&#x2013;798.</Citation></Reference><Reference><Citation>H. E. Bays, C. Kirkpatrick, K. C. Maki, et&#xa0;al., &#x201c;Obesity, Dyslipidemia, and Cardiovascular Disease: A Joint Expert Review From the Obesity Medicine Association and the National Lipid Association 2024,&#x201d; Journal of Clinical Lipidology 10 (2024): 100108.</Citation></Reference><Reference><Citation>S. M. Fruh, &#x201c;Obesity: Risk Factors, Complications, and Strategies for Sustainable Long&#x2010;Term Weight Management,&#x201d; Journal of the American Association of Nurse Practitioners 29, no. S1 (2017): S3&#x2013;S14.</Citation></Reference><Reference><Citation>W. P. James, A. Astrup, N. Finer, et&#xa0;al., &#x201c;Effect of Sibutramine on Weight Maintenance After Weight Loss: A Randomised Trial,&#x201d; Lancet 356, no. 9248 (2000): 2119&#x2013;2125.</Citation></Reference><Reference><Citation>S. R. Smith, N. J. Weissman, C. M. Anderson, et&#xa0;al., &#x201c;Multicenter, Placebo&#x2010;Controlled Trial of Lorcaserin for Weight Management,&#x201d; New England Journal of Medicine 363, no. 3 (2010): 245&#x2013;256.</Citation></Reference><Reference><Citation>T. A. Wadden, P. Hollander, S. Klein, et&#xa0;al., &#x201c;Weight Maintenance and Additional Weight Loss With Liraglutide After Low&#x2010;Calorie&#x2010;Diet&#x2010;Induced Weight Loss: The SCALE Maintenance Randomized Study,&#x201d; International Journal of Obesity 37, no. 11 (2013): 1443&#x2013;1451.</Citation></Reference><Reference><Citation>D. Rubino, N. Abrahamsson, M. Davies, et&#xa0;al., &#x201c;Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial,&#x201d; JAMA 325, no. 14 (2021): 1414&#x2013;1425.</Citation></Reference><Reference><Citation>L. Sj&#xf6;str&#xf6;m, M. Peltonen, P. Jacobson, et&#xa0;al., &#x201c;Bariatric Surgery and Long&#x2010;Term Cardiovascular Events,&#x201d; JAMA 307, no. 1 (2012): 56&#x2013;65.</Citation></Reference><Reference><Citation>A. Mentias, A. Aminian, D. Youssef, et&#xa0;al., &#x201c;Long&#x2010;Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare Population,&#x201d; Journal of the American College of Cardiology 79, no. 15 (2022): 1429&#x2013;1437.</Citation></Reference><Reference><Citation>A. M. Lincoff, K. Brown&#x2010;Frandsen, H. M. Colhoun, et&#xa0;al., &#x201c;Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes,&#x201d; New England Journal of Medicine 389, no. 24 (2023): 2221&#x2013;2232.</Citation></Reference><Reference><Citation>J. P. H. Wilding, R. L. Batterham, M. Davies, et&#xa0;al., &#x201c;Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension,&#x201d; Diabetes, Obesity &amp; Metabolism 24, no. 8 (2022): 1553&#x2013;1564.</Citation></Reference><Reference><Citation>L. J. Aronne, N. Sattar, D. B. Horn, et&#xa0;al., &#x201c;Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT&#x2010;4 Randomized Clinical Trial,&#x201d; JAMA 331, no. 1 (2024): 38&#x2013;48.</Citation></Reference><Reference><Citation>&#x201c;A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT&#x2010;MMO),&#x201d; https://clinicaltrials.gov/study/NCT05556512.</Citation></Reference><Reference><Citation>A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et&#xa0;al., &#x201c;Tirzepatide Once Weekly for the Treatment of Obesity,&#x201d; New England Journal of Medicine 387, no. 3 (2022): 205&#x2013;216.</Citation></Reference><Reference><Citation>W. T. Garvey, J. P. Frias, A. M. Jastreboff, et&#xa0;al., &#x201c;Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT&#x2010;2): A Double&#x2010;Blind, Randomised, Multicentre, Placebo&#x2010;Controlled, Phase 3 Trial,&#x201d; Lancet 402, no. 10402 (2023): 613&#x2013;626.</Citation></Reference><Reference><Citation>T. A. Wadden, A. M. Chao, S. Machineni, et&#xa0;al., &#x201c;Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: The SURMOUNT&#x2010;3 Phase 3 Trial,&#x201d; Nature Medicine 29, no. 11 (2023): 2909&#x2013;2918.</Citation></Reference><Reference><Citation>World Medical Association, &#x201c;World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects,&#x201d; JAMA 310, no. 20 (2013): 2191&#x2013;2194.</Citation></Reference><Reference><Citation>T. Coskun, K. W. Sloop, C. Loghin, et&#xa0;al., &#x201c;LY3298176, a Novel Dual GIP and GLP&#x2010;1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept,&#x201d; Molecular Metabolism 18 (2018): 3&#x2013;14.</Citation></Reference><Reference><Citation>J. P. Frias, M. A. Nauck, J. Van, et&#xa0;al., &#x201c;Efficacy and Safety of LY3298176, a Novel Dual GIP and GLP&#x2010;1 Receptor Agonist, in Patients With Type 2 Diabetes: A Randomised, Placebo&#x2010;Controlled and Active Comparator&#x2010;Controlled Phase 2 Trial,&#x201d; Lancet 392, no. 10160 (2018): 2180&#x2013;2193.</Citation></Reference><Reference><Citation>J. Rosenstock, C. Wysham, J. P. Frias, et&#xa0;al., &#x201c;Efficacy and Safety of a Novel Dual GIP and GLP&#x2010;1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS&#x2010;1): A Double&#x2010;Blind, Randomised, Phase 3 Trial,&#x201d; Lancet 398, no. 10295 (2021): 143&#x2013;155.</Citation></Reference><Reference><Citation>J. P. Frias, M. J. Davies, J. Rosenstock, et&#xa0;al., &#x201c;Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes,&#x201d; New England Journal of Medicine 385, no. 6 (2021): 503&#x2013;515.</Citation></Reference><Reference><Citation>B. Ludvik, F. Giorgino, E. Jodar, et&#xa0;al., &#x201c;Once&#x2010;Weekly Tirzepatide Versus Once&#x2010;Daily Insulin Degludec as Add&#x2010;On to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS&#x2010;3): A Randomised, Open&#x2010;Label, Parallel&#x2010;Group, Phase 3 Trial,&#x201d; Lancet 398, no. 10300 (2021): 583&#x2013;598.</Citation></Reference><Reference><Citation>S. Del Prato, S. E. Kahn, I. Pavo, et&#xa0;al., &#x201c;Tirzepatide Versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS&#x2010;4): A Randomised, Open&#x2010;Label, Parallel&#x2010;Group, Multicentre, Phase 3 Trial,&#x201d; Lancet 398 (2021): 1811&#x2013;1824.</Citation></Reference><Reference><Citation>D. Dahl, Y. Onishi, P. Norwood, R. Huh, H. Patel, and A. Rodr&#xed;guez, &#x201c;Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS&#x2010;5 Randomized Clinical Trial,&#x201d; JAMA 327, no. 6 (2022): 534&#x2013;545.</Citation></Reference><Reference><Citation>K. Kroenke, R. L. Spitzer, and J. B. Williams, &#x201c;The PHQ&#x2010;9: Validity of a Brief Depression Severity Measure,&#x201d; Journal of General Internal Medicine 16, no. 9 (2001): 606&#x2013;613.</Citation></Reference><Reference><Citation>K. Posner, G. K. Brown, B. Stanley, et&#xa0;al., &#x201c;The Columbia&#x2010;Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults,&#x201d; American Journal of Psychiatry 168, no. 12 (2011): 1266&#x2013;1277.</Citation></Reference><Reference><Citation>Columbia Lighthouse Project, &#x201c;The Columbia Protocol (C&#x2010;SSRS),&#x201d; accessed March 25, 2025, https://cssrs.columbia.edu/the&#x2010;columbia&#x2010;scale&#x2010;c&#x2010;ssrs/about&#x2010;the&#x2010;scale/.</Citation></Reference><Reference><Citation>D. B. Rubin, Multiple Imputation for Nonresponse in Surveys (John Wiley &amp; Sons Inc., 1987).</Citation></Reference><Reference><Citation>J. C. Cappelleri, A. G. Bushmakin, R. A. Gerber, et&#xa0;al., &#x201c;Evaluating the Power of Food Scale in Obese Subjects and a General Sample of Individuals: Development and Measurement Properties,&#x201d; International Journal of Obesity 33, no. 8 (2009): 913&#x2013;922.</Citation></Reference><Reference><Citation>M. R. Lowe, M. L. Butryn, E. R. Didie, et&#xa0;al., &#x201c;The Power of Food Scale. A New Measure of the Psychological Influence of the Food Environment,&#x201d; Appetite 53, no. 1 (2009): 114&#x2013;118.</Citation></Reference><Reference><Citation>A. Meule, T. Hermann, and A. K&#xfc;bler, &#x201c;A Short Version of the Food Cravings Questionnaire&#x2010;Trait: The FCQ&#x2010;T&#x2010;Reduced,&#x201d; Frontiers in Psychology 5 (2014): 190.</Citation></Reference><Reference><Citation>M. E. Maruish, ed., User's Manual for the SF&#x2010;36v2 Health Survey, 3rd ed. (Lincoln, RI, 2011).</Citation></Reference><Reference><Citation>W. T. Garvey, J. I. Mechanick, E. M. Brett, et&#xa0;al., &#x201c;American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients With Obesity,&#x201d; Endocrine Practice 22, no. Suppl 3 (2016): 1&#x2013;203.</Citation></Reference><Reference><Citation>FDA (Food and Drug Administration), &#x201c;Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction, Guidance for Industry, &#x201d; 2025, https://www.fda.gov/media/71252/download.</Citation></Reference><Reference><Citation>J. Stevens, K. P. Truesdale, J. E. McClain, and J. Cai, &#x201c;The Definition of Weight Maintenance,&#x201d; International Journal of Obesity 30, no. 3 (2006): 391&#x2013;399.</Citation></Reference><Reference><Citation>S. E. Berger, G. S. Huggins, J. M. McCaffery, P. F. Jacques, and A. H. Lichtenstein, &#x201c;Change in Cardiometabolic Risk Factors Associated With Magnitude of Weight Regain 3&#x2009;Years After a 1&#x2010;Year Intensive Lifestyle Intervention in Type 2 Diabetes Mellitus: The Look AHEAD Trial,&#x201d; Journal of the American Heart Association 8, no. 20 (2019): e010951.</Citation></Reference><Reference><Citation>W. C. King, A. S. Hinerman, S. H. Belle, A. S. Wahed, and A. P. Courcoulas, &#x201c;Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes,&#x201d; JAMA 320, no. 15 (2018): 1560&#x2013;1569.</Citation></Reference><Reference><Citation>A. M. Jastreboff, C. W. le Roux, A. Stefanski, et&#xa0;al., &#x201c;Tirzepatide for Obesity Treatment and Diabetes Prevention,&#x201d; New England Journal of Medicine 392 (2024): 958.</Citation></Reference><Reference><Citation>&#x201c;A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight&#x2010;Related Comorbidities (ATTAIN&#x2010;MAINTAIN),&#x201d; https://clinicaltrials.gov/study/NCT06584916.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>